CSPC Pharmaceutical Statistics
Share Statistics
CSPC Pharmaceutical has 11.47B
shares outstanding. The number of shares has increased by -2.89%
in one year.
| Shares Outstanding | 11.47B |
| Shares Change (YoY) | -2.89% |
| Shares Change (QoQ) | -0.82% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 15.13M, so 0% of the outstanding
shares have been sold short.
| Short Interest | 15.13M |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 999.99 |
Valuation Ratios
The PE ratio is 12.43 and the forward
PE ratio is 13.5.
CSPC Pharmaceutical's PEG ratio is
-0.51.
| PE Ratio | 12.43 |
| Forward PE | 13.5 |
| PS Ratio | 1.85 |
| Forward PS | 2.1 |
| PB Ratio | 1.67 |
| P/FCF Ratio | 28.99 |
| PEG Ratio | -0.51 |
Financial Ratio HistoryEnterprise Valuation
CSPC Pharmaceutical has an Enterprise Value (EV) of 47.53B.
| EV / Sales | 1.64 |
| EV / EBITDA | 6.83 |
| EV / EBIT | 10.48 |
| EV / FCF | 25.61 |
Financial Position
The company has a current ratio of 2.27,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.27 |
| Quick Ratio | 1.95 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.27 |
| Interest Coverage | 122.87 |
Financial Efficiency
Return on Equity is 13.41% and Return on Invested Capital is 11.85%.
| Return on Equity | 13.41% |
| Return on Assets | 9.75% |
| Return on Invested Capital | 11.85% |
| Revenue Per Employee | $1,355,572.62 |
| Profits Per Employee | $202,244.63 |
| Employee Count | 21,400 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.78 |
Taxes
| Income Tax | 1.24B |
| Effective Tax Rate | 22.23% |
Stock Price Statistics
The stock price has increased by -3.57% in the
last 52 weeks. The beta is 0.72, so CSPC Pharmaceutical's
price volatility has been higher than the market average.
| Beta | 0.72 |
| 52-Week Price Change | -3.57% |
| 50-Day Moving Average | 0.61 |
| 200-Day Moving Average | 0.65 |
| Relative Strength Index (RSI) | 99.82 |
| Average Volume (20 Days) | 2,290 |
Income Statement
In the last 12 months, CSPC Pharmaceutical had revenue of 29.01B
and earned 4.33B
in profits. Earnings per share was 0.37.
| Revenue | 29.01B |
| Gross Profit | 20.3B |
| Operating Income | 5.37B |
| Net Income | 4.33B |
| EBITDA | 6.96B |
| EBIT | 5.62B |
| Earnings Per Share (EPS) | 0.37 |
Full Income StatementBalance Sheet
The company has 6.78B in cash and 507.33M in
debt, giving a net cash position of 6.27B.
| Cash & Cash Equivalents | 6.78B |
| Total Debt | 507.33M |
| Net Cash | 6.27B |
| Retained Earnings | 23.34B |
| Total Assets | 44.39B |
| Working Capital | 12.25B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 4.53B
and capital expenditures -2.68B, giving a free cash flow of 1.86B.
| Operating Cash Flow | 4.53B |
| Capital Expenditures | -2.68B |
| Free Cash Flow | 1.86B |
| FCF Per Share | 0.16 |
Full Cash Flow StatementMargins
Gross margin is 69.97%, with operating and profit margins of 18.5% and 14.92%.
| Gross Margin | 69.97% |
| Operating Margin | 18.5% |
| Pretax Margin | 19.23% |
| Profit Margin | 14.92% |
| EBITDA Margin | 24% |
| EBIT Margin | 18.5% |
| FCF Margin | 6.4% |
